Medication-related barriers to entering HIV care

AIDS Patient Care STDS. 2012 Apr;26(4):214-21. doi: 10.1089/apc.2011.0407. Epub 2012 Feb 9.

Abstract

Early entry to HIV care and receipt of antiretroviral therapy improve the health of the individual and decrease the risk of transmission in the community. To increase the limited information on prospective decisions to enter care and how these decisions relate to beliefs about HIV medications, we analyzed interview data from the Never in Care Project, a multisite project conducted in Indiana, New Jersey, New York City, Philadelphia, and Washington State. From March 2008 through August 2010, we completed structured interviews with 134 persons with no evidence of HIV care entry, 48 of whom also completed qualitative interviews. Many respondents believed that HIV care entails the passive receipt of medications that may be harmful or unnecessary, resulting in reluctance to enter care. Respondents voiced concerns about prescription practices and preserving future treatment options, mistrust of medications and medical care providers, and ambivalence about the life-preserving properties of medications in light of an assumed negative impact on quality of life. Our results support the provision of information on other benefits of care (beyond medications), elicitation of concerns about medications, and assessment of psychosocial barriers to entering care. These tasks should begin at the time a positive test result is delivered and continue throughout the linkage-to-care process; for persons unwilling to enter care immediately, support should be provided in nonmedical settings.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Continuity of Patient Care / statistics & numerical data*
  • Female
  • Guideline Adherence
  • HIV Seropositivity / drug therapy*
  • HIV Seropositivity / psychology
  • Humans
  • Male
  • Patient Compliance* / statistics & numerical data
  • Patient Satisfaction
  • Referral and Consultation
  • United States
  • Young Adult

Substances

  • Anti-HIV Agents